临床试验

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT：NCT07593209 · RECRUITING

NCT编号NCT07593209

状态RECRUITING

开始日期2026-05-01

完成时间2027-12-31

SponsorFirst Hospital of China Medical University (OTHER)

First posted2026-05-18

Last updated2026-05-18

简要摘要

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。